The world should closely watch what happens next. If implemented carefully, New Zealand’s new laws offer the first genuinely scientific and public health-oriented approach to dealing with the negative aspects of humanity’s eternal quest for consciousness alteration.
Anthropology tells us that getting high is universal — no culture, no matter how remote, lacks chemical experimentation.
After all, few existing U.S. drug laws were based on a medical assessment of the relative risks of alcohol, tobacco, marijuana, heroin, cocaine and others. Instead, they were derived from historical contingencies and, typically, explicit racism.
The first state laws against cocaine, for example, were passed because the drug was believed to make blacks into “fiends” who would rape white women and be impervious to bullets. The first state laws against opium made similar claims about its effects on Chinese railroad workers — and marijuana prohibition followed a scare campaign about its link with Mexicans and blacks and ability to promote violence and interracial liaisons.
By contrast, New Zealand’s new laws specify that products with “low risk” of death, other harms or addiction must be approved — and leaves it up to a scientific committee to define the precise nature and appropriate definition of “low risk.” Drugs that are already illegal will remain so, probably to avoid conflict with international law. The legislation makes no mention of benefits or efficacy, so manufacturers do not have to prove that their drugs are better than placebos.
At least six drugs have already been rejected. However, the law allowed marketers to keep selling products they have submitted for approval, if they’d already been marketed without incident for at least three months. (The rationale was that since bans cannot keep up, it is futile to add more while the approval process is starting.)
Not surprisingly, all new drugs will remain illegal for people under 18. They can only be sold at specific, licensed outlets — not convenience stores or other places frequented by youth — and must carry packaging identifying the ingredients and including health warnings about the known and potential risks. No advertising is permitted, except inside the store itself.
Will this legislation work? It’s certainly an improvement on the current system, which essentially allows new drugs to be marketed worldwide without testing. It also avoids problems with attempts — like pending legislation on which hearings were held last month in the U.S. Senate — to create blanket bans on all possible analogues of existing psychoactive drugs.
Such prohibitions not only fail to stop chemists from creating newer compounds, but also cause serious problems for healthcare. Many of these substances have potential medical uses — in fact, they are often based on information from pharmaceutical patent applications — but once they are made illegal, drug companies tend to lose interest because of the excess cost and greater risk of rejection when seeking approval. The former top adviser to the British government on drug policy, Dr. David Nutt, has compared the loss to medicine that results to the delays in scientific advancement caused by the Catholic church’s actions against Galileo and Copernicus.
http://blogs.reuters.com/great-debate/2 ... nal-drugs/